Add to ORKGThe study reaffirms the safety and efficacy of the Vi polysaccharide vaccine and identifies a hitherto unrecognized advantage in its use, i.e. it is a potent immunogen that boosted considerably the protective antibody levels among a significant number of immunologically sensitized individuals living in typhoid-endemic regions
AbstractBackgroundAlthough typhoid fever is rare in Japan, imported cases have been reported occasio...
Background: Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly wor...
Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent anti...
Background: The recent emergence of multi-drug-resistant Salmonella strains highlights the need for ...
Typhoid fever remains an important public health problem globally. Cluster randomized effectiveness ...
Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric...
Typhoid fever is a disease predominant in underdeveloped and developing countries. Typhoid fever is ...
in European adults. (1·25 µg, 5·0 µg and 12·5 µg of Vi antigen) with the polysaccharide vaccine. fo...
Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in end...
A typhoid vaccine derived from the purified Vi capsular polysaccharide (CPS) antigen of Salmonella t...
Typhoid fever remains a serious problem in developing countries. Current vaccines are licensed for i...
BACKGROUND: Typhoid fever is endemic in Karachi, with an incidence among children ranging from 170 t...
Each year, 12.1 to 20.6 million typhoid fever infections occur globally, of which 1% result in death...
Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections an...
Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in end...
AbstractBackgroundAlthough typhoid fever is rare in Japan, imported cases have been reported occasio...
Background: Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly wor...
Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent anti...
Background: The recent emergence of multi-drug-resistant Salmonella strains highlights the need for ...
Typhoid fever remains an important public health problem globally. Cluster randomized effectiveness ...
Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric...
Typhoid fever is a disease predominant in underdeveloped and developing countries. Typhoid fever is ...
in European adults. (1·25 µg, 5·0 µg and 12·5 µg of Vi antigen) with the polysaccharide vaccine. fo...
Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in end...
A typhoid vaccine derived from the purified Vi capsular polysaccharide (CPS) antigen of Salmonella t...
Typhoid fever remains a serious problem in developing countries. Current vaccines are licensed for i...
BACKGROUND: Typhoid fever is endemic in Karachi, with an incidence among children ranging from 170 t...
Each year, 12.1 to 20.6 million typhoid fever infections occur globally, of which 1% result in death...
Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections an...
Vi-polysaccharide conjugate vaccines are efficacious against typhoid fever in children living in end...
AbstractBackgroundAlthough typhoid fever is rare in Japan, imported cases have been reported occasio...
Background: Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly wor...
Vaccination against Salmonella Typhi using the Vi capsular polysaccharide, a T-cell independent anti...